Agilon Health, Inc. Soars to New 52-Week High of $93.89

Agilon Health, Inc. has reached a significant milestone by hitting a new 52-week high of USD 93.89 on May 29, 2026. This achievement marks a remarkable performance for the small-cap company within the Pharmaceuticals & Biotechnology sector, showcasing a staggering 1,277.31% increase over the past year, significantly outpacing the S&P 500's 28.21% growth during the same period. With a market capitalization of USD 247 million, Agilon Health continues to attract attention in the market. Despite its impressive stock performance, the company remains in a loss-making position, reflected in its negative price-to-earnings ratio and return on equity of -102.82%. The stock's price-to-book ratio stands at 0.81, indicating its valuation relative to its net assets. As Agilon Health continues to navigate the competitive landscape of the pharmaceuticals and biotechnology industry, this new high underscores its notable progress and resilience in a challenging market environment.